NR3C1 and prostate carcinoma: Venkitaraman et al.[77] demonstrated that glucocorticoids inhibit lymphangiogenesis through vascular endothelial growth factor downregulation and inhibit prostate cancer cell proliferation through the glucocorticoid receptor induction.